Head-To-Head Comparison: KemPharm

Head-To-Head Comparison: KemPharm

KemPharm and Cyclacel Pharmaceuticals are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations and earnings. KemPharm presently has a consensus target price of $12.00, suggesting a potential upside of 84.62%.

from Biotech News

Комментариев нет:

Отправить комментарий

Pharmacy News Digest

Архив блога